Session: Morbidity and Mortality of HIV-1 Infection

Home

Session 120 Poster Abstracts
Morbidity and Mortality of HIV-1 Infection
Monday, 1:30 - 3:30 pm
Poster Hall


869	Use of Total Lymphocyte Counts and Hemoglobin Concentration for Monitoring Progression to AIDS B Lau¹, S Gange¹, J Phair², S Riddler³, R Detels⁴, J Margolick¹, and Multicenter AIDS Cohort Study ¹Johns Hopkins Univ., Baltimore, MD, USA; ²Northwestern Med. Sch., Chicago, IL, USA; ³Univ. of Pittsburgh, PA, USA; and ⁴Univ. of California, Los Angeles, USA*
870	Survival after Diagnosis with Heterosexually Acquired AIDS, United States, 1996-2002 L Espinoza, R Selik, and H I Hall CDC, Atlanta, GA, USA*
871	The Proportion of Deaths Due to HIV Infection among Persons with AIDS in New York City and San Francisco during 1987 to 1999 R Selik¹, T Singh², and L Hsu³ ¹CDC, Atlanta, GA, USA; ²New York City Dept. of Hlth. and Mental Hygiene, NY, USA; and ³San Francisco Dept. of Publ. Hlth., CA, USA*
872	Mortality and Morbidity in the HAART Era: Changing Causes of Death and Disease in the HIV Outpatient Study F J Palella Jr¹, R Baker², A C Moorman³, J Chmiel¹, K Wood², S D Holmberg³, and the HOPS Investigators ¹Northwestern Univ., Chicago, IL, USA; ²Cerner Corp., Herndon, VA, USA; and ³CDC, Atlanta, GA, USA*
873	Mortality in the HIV Atlanta VA Cohort Study: A 22-Year Analysis D Rimland², and J Guest² ¹Emory Univ. Sch. of Med., Atlanta, GA, USA and ²VA Med. Ctr., Atlanta, GA, USA*
874	The Effect of Non-AIDS Serious Adverse Events Equals or Exceeds that of AIDS Outcomes in Patients with Advanced Mullti-drug Resistant HIV Disease S T Brown*^1,2, J Singer³, A Anis³, H Sun³, T C Kyriakides⁴, B J Angus^5,6, K Swanson⁷, W Cameron⁸, A Babiker⁶, M Holodniy⁹, and The OPTIMA Study Team ¹Bronx VA Med. Ctr., NY, USA; ²Mt. Sinai Sch. Med, New York, NY, USA; ³HIV Clin. Trials Network, Vancouver, Canada; ⁴VA Cooperative Studies Prgm. Coordinating Ctr., West Haven, CT, USA; ⁵Univ. of Oxford, Headington, UK; ⁶Med. Res. Council Clin. Trials Unit, London, UK; ⁷VA Cooperative Studies Prgm., Albuquerque, NM, USA; ⁸Ottawa Hosp, Ontario, Canada; and ⁹VA Palo Alto, CA, USA
875	Malignancies-related Causes of Death of HIV-infected Patients in the Era of Highly Active Antiretroviral Therapy F Bonnet*¹, C Lewden², D May³, L Heripret⁴, E Jougla⁵, D Costagliola⁶, D Salmon⁷, G Chêne², P Morlat¹, and the Groupe Mortalité 2000. ¹CHU Bordeaux, France.; ²INSERM U593, Bordeaux, France.; ³CHU Nancy, France; ⁴CHU Nice, France; ⁵CépiDc INSERM, Le Vésinet, France; ⁶INSERM EPI 0214, Paris, France.; and ⁷CHU Cochin, Paris, France
876	The Effect of HIV on the Patterns of Death at an Urban Hospital in South Africa W D F Venter¹, U Jentsch*², L E Isherwood², D Schulze², I Jaffray², S James², C van der Horst³, G Chita⁴, and I M Sanne² ¹Univ. of the Witwatersrand, Reproductive Hlth. Res. Unit, Johannesburg, South Africa; ²Clin. HIV Res. Unit, Univ. of the Witwatersrand, Johannesburg, South Africa; ³Univ. of North Carolina at Chapel Hill, USA; and ⁴Helen Joseph Hosp., Univ. of the Witwatersrand, Johannesburg, South Africa
877	Incidence of and Risk Factors for Infective Endocarditis in an Urban HIV Cohort L Wilson, R Moore, M Burkey, and K Gebo Johns Hopkins Univ. Sch. of Med., Baltimore, MD, USA*
878	History of Acute Pancreatitis and Hepatitis C Virus Infection Increase the Risk of New-onset Diabetes among HIV-infected Patients H Crane, S Van Rompaey, and M Kitatata Univ. of Washington, Seattle, USA*
879	A Tale of 2 Epidemics: The Intersection between Obesity and HIV Infection in the Urban United States V Amorosa, M Synnestvedt, R Gross, I Frank, H Friedman, R MacGregor, D Guidonis, P Tebas, and University of Pennsylvania Center for AIDS Research and AIDS Clinical Trials Unit Univ. of Pennsylvania, Philadelphia, USA*
880	Modeling the Sexual Synergy between HSV-2 and HIV-1 Epidemics S Blower¹, T Porco², F Wang¹, A Wald³, and L Corey³ ¹Univ. of California, Los Angeles, USA; ²San Francisco Dept. of Publ. Hlth., CA, USA; and ³Univ. of Washington, Seattle, USA*